Opko shares are pinned to success with new diagnostic tests, Barron's says

theflyonthewall.com

Opko Health (OPK) one of the most heavily shorted companies on the NYSE. However, Billionaire investor and entrepreneur Phillip Frost, who owns 39% of the stock, has made a big bet on this small medical company. A stock analyst at Ladenburg projected as much as $3B in annual sales for its Alzheimer's blood test and told investors to expect validation of its biomarker technology by mid-2012. Opko's other leading diagnostics program is a prostate-cancer test. Opko shares are worth $1 or $2 at best unless its new diagnostic tests are successful, Barron's contends. Validation studies haven't been as positive as early claims. The shares trade at $4.18.

View Comments (0)